Xenetic Biosciences (XBIO) Change in Accured Expenses (2011 - 2026)
Xenetic Biosciences' (XBIO) quarterly Change in Accured Expenses came in at -$9786.0 in Q1 2026, up 95.68% YoY from -$5001.1 in Q1 2025, and up 93.19% on a QoQ basis from -$143750.0 in Q4 2025.
Xenetic Biosciences (XBIO) Change in Accured Expenses (2011 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 16 years of Change in Accured Expenses data on file, last reported at -$9786.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 95.68% year-over-year to -$9786.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $290312.0 (up 697.76% YoY) and the FY2025 annual result came in at $73762.0, down 12.89% from the prior year.
- Change in Accured Expenses advanced to -$9786.0 in Q1 2026, from -$143750.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $871108.0 in Q2 2024 to a low of -$578195.0 in Q3 2024.
- A 5-year average of -$27227.3 and a median of -$93091.0 in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses sank 1261.14% — and 2024, when it surged 5726.81%.
- Tracing XBIO's Change in Accured Expenses over 5 years: stood at $22298.0 in 2022, then slumped by 1261.14% to -$258912.0 in 2023, then jumped by 55.53% to -$115144.0 in 2024, then decreased by 24.84% to -$143750.0 in 2025, then jumped by 93.19% to -$9786.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$9786.0 (Q1 2026), -$143750.0 (Q4 2025), and $208345.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - | -63,262.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -63,262.00 |
| Jun 30, 2026 | -63,262.00 |
| Mar 31, 2026 | -9,786.00 |
| Mar 31, 2026 | -9,786.00 |
| Dec 31, 2025 | -143,750.00 |
| Dec 31, 2025 | -143,750.00 |
| Sep 30, 2025 | 208,345.00 |
| Sep 30, 2025 | 208,345.00 |
| Jun 30, 2025 | 235,503.00 |
| Jun 30, 2025 | 235,503.00 |
| Mar 31, 2025 | -226,336.00 |
| Mar 31, 2025 | -226,336.00 |
| Dec 31, 2024 | -115,144.00 |
| Dec 31, 2024 | -115,144.00 |
| Sep 30, 2024 | -578,195.00 |
| Sep 30, 2024 | -578,195.00 |
| Jun 30, 2024 | 871,108.00 |
| Jun 30, 2024 | 871,108.00 |
| Mar 31, 2024 | -93,091.00 |
| Mar 31, 2024 | -93,091.00 |